Global Daily Briefing

AMZN +15.32% is the single largest single-day dollar gain among US mega-caps in months. The move validated the thesis — articulated in Sarah's US brief — that the S&P 500 is on track for its strongest five-year earnings cycle, driven by hyperscaler cloud demand, AI monetization, and consumer e-commerce resilience. The cross-market read: any APAC semiconductor name with AWS supply-chain exposure (Samsung, SK Hynix, TSMC) should gap up on Monday's Asia open as cloud AI capex signals remain robust. Nasdaq 100 futures fair value is materially positive heading into Monday's Asian session.

The FT's report of AstraZeneca exploring a $400bn acquisition of Bristol Myers Squibb is this week's defining M&A event. AZN is a FTSE 100 heavyweight; BMY is a S&P 500 large-cap. A combined entity would rank among the world's top-3 drugmakers by revenue, creating an oncology and immunology platform that would dwarf most competitors. As Eva noted in the UK brief, AZN's funding structure and dividend cover are the near-term investor concerns. For cross-market flows, any BMY deal confirmation would trigger a wave of pharma index rebalancing — MSCI World Healthcare constituents will see positioning shifts as deal premium repricing flows through both US and European tracker funds.

Two simultaneous oil-supply developments arrived today: Trump held off Iran strikes after Hormuz talks advanced, and OPEC+ approved a small quota increase to complete unwinding its 2023 cuts. Together, these events are removing the emergency geopolitical premium that had been supporting Brent in the $95-110 range. As Marcus noted in the Brazil and Canada briefs, this creates divergent impacts: energy-importing EMs (India, Korea) benefit from lower import costs, while oil-exporters (Canada, Brazil, Gulf) face near-term revenue pressure. For cross-asset traders: watch the Brent front-month contract and the 1/6 calendar spread — a flattening backwardation structure signals that the supply-risk premium is genuinely deflating.